During a routine follow-up visit at the public health clinic, a physician evaluates an asy… — USMLE Step 3

During a routine follow-up visit at the public health clinic, a physician evaluates an asymptomatic patient who recently began treatment for latent tuberculosis infection. Four weeks ago, the patient had a positive interferon-gamma release assay with a normal chest radiograph, leading to the initiation of daily isoniazid and pyridoxine.

The patient currently reports feeling entirely well, specifically denying fatigue, nausea, vomiting, abdominal pain, jaundice, or changes in urine color.

Recent laboratory studies show the following:

Test	Result	Reference Range
Aspartate aminotransferase (AST)	$115$ U/L	$8$ - $40$ U/L
Alanine aminotransferase (ALT)	$130$ U/L	$7$ - $56$ U/L
Total bilirubin	$0.8$ mg/dL	$0.1$ - $1.2$ mg/dL

Which of the following is the most appropriate next step in the management of this patient?

A
Order an abdominal computed tomography scan
B
Discontinue isoniazid and admit to the hospital for close observation
Continue the current regimen and repeat liver function tests in $2$ to $4$ weeksAnswer
D
Maintain the current regimen and order an ultrasound-guided liver biopsy
E
Discontinue isoniazid and initiate oral rifampin monotherapy

Answer

Continue the current regimen and repeat liver function tests in

2

4

weeks

The correct answer is to continue the current regimen and repeat liver function tests. Isoniazid (INH) is a standard treatment for latent tuberculosis but is well-known to cause hepatotoxicity. However, up to

10\%

20\%

of patients develop a transient, mild elevation in hepatic aminotransferases during the first few months of therapy, a phenomenon termed hepatic adaptation. According to established guidelines, INH therapy should only be discontinued if the aminotransferases (AST or ALT) rise to greater than

3

times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), or greater than

5

times the ULN even in the absence of symptoms. In this scenario, the patient is entirely asymptomatic and the AST and ALT levels are only about

2

3

times the ULN (e.g., ALT is

130

U/L compared to a normal upper limit of

56

U/L). Therefore, the threshold for stopping the drug has not been met. The most appropriate clinical decision is to maintain the current medication and repeat the liver function tests in

2

4

weeks to ensure the transaminitis resolves or remains stable.

Step-by-Step Solution

Analyze the patient's current symptoms and laboratory findings in the context of their medication regimen.

The patient is taking isoniazid and has mild, asymptomatic transaminitis (AST and ALT are roughly

2.5

3

times the upper limit of normal).

Establishing the severity and symptomatic nature of the transaminitis is required to apply the correct management algorithm.

Apply the standard treatment monitoring guidelines for isoniazid-induced hepatotoxicity.

Guidelines dictate stopping isoniazid only if AST/ALT is >

3

times the upper limit of normal with symptoms, or >

5

times the upper limit of normal without symptoms.

Differentiating between benign hepatic adaptation and true drug-induced liver injury prevents inappropriate discontinuation of a necessary medication.

Determine the best next step based on the guideline criteria.

Because the transaminases are <

5

times normal and the patient lacks symptoms, the medication should be continued while scheduling repeat laboratory testing in

2

4

weeks.

This strategy safely monitors for progression to severe toxicity while allowing completion of latent tuberculosis treatment if values stabilize or improve.

Key Concept

Monitoring parameters and thresholds for discontinuation of isoniazid due to hepatotoxicity versus benign hepatic adaptation.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic